TABLE 3.
Yr and isolate | ESBL | MIC (μg/ml)a
|
Resistance phenotype | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMC | PIP | P/T | FOX | CTX | CTX-C | CAZ | CAZ-C | CPM | ATM | IMP | |||
1991 | |||||||||||||
Ec13 | TEM-4 | ≤4/2 | >64 | ≤16/4 | ≤2 | >8 | ≤0.12/4 | 4 | ≤0.12/4 | 16 | 8 | ≤0.5 | |
Ec14 | TEM-4 | 8/4 | >64 | 32/4 | 4 | >8 | ≤0.12/4 | 16 | ≤0.12/4 | 8 | 8 | ≤0.5 | St Sp Gm Tb Net Nm Nal Cip Tet Sul Tp |
Ec15 | TEM-4 | 8/4 | >64 | ≤16/4 | ≤2 | >8 | ≤0.12/4 | 16 | ≤0.12/4 | 32 | 16 | ≤0.5 | St Gm Tb Nal Cip Tet Sul |
Ec16 | CTX-M-10 | 8/4 | >64 | ≤16/4 | ≤2 | >8 | ≤0.12/4 | 2 | ≤0.12/4 | 32 | 64 | ≤0.5 | |
Kp30 | CTX-M-10 | 8/4 | >64 | ≤16/4 | ≤2 | >8 | ≤0.12/4 | 8 | ≤0.12/4 | >32 | >64 | ≤0.5 | |
CF | CTX-M-10 | 8/4 | >64 | ≤16/4 | >16 | >8 | ≤0.12/4 | 8 | ≤0.12/4 | 32 | 64 | ≤0.5 | |
2003 | |||||||||||||
Fec 231 | TEM-4 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 16 | ≤0.12/4 | 32 | 8 | ≤0.5 | |
Fec 355 | TEM-4 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 8 | ≤0.12/4 | 8 | 16 | ≤0.5 | St |
Fec 295 | TEM-52 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 32 | ≤0.12/4 | >32 | 8 | ≤0.5 | St Nal Tet Sul Tp Clo |
Fec 394 | SHV-2 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 8 | ≤0.12/4 | 32 | 16 | ≤0.5 | Tet Sul Tp Clo |
Fec 284Z | SHV-12 | ≤4/2 | >64 | ≤16/4 | ≤2 | 128 | ≤0.12/4 | 128 | ≤0.12/4 | 32 | 64 | ≤0.5 | Tet Sul Clo |
Fec 335 | SHV-12 | ≤4/2 | >64 | ≤16/4 | ≤2 | 64 | ≤0.12/4 | 64 | ≤0.12/4 | 32 | 32 | ≤0.5 | Sul Clo |
Fec 222 | SHV-12 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | >128 | ≤0.12/4 | 32 | ≤0.5 | ||
Fec 250 | SHV-12 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | >128 | ≤0.12/4 | >32 | 64 | ≤0.5 | Nal Sul Clo |
Fec 251 | SHV-12 | ≤4/2 | >64 | ≤16/4 | 4 | 128 | ≤0.12/4 | 128 | ≤0.12/4 | 32 | 64 | ≤0.5 | Nal Sul Clo |
Fec 310 | SHV-12 | ≤4/2 | >64 | ≤16/4 | 4 | 128 | ≤0.12/4 | 128 | ≤0.12/4 | 32 | 32 | ≤0.5 | Nal Cip Tet Sul Clo |
Fec 340 | SHV-12 | ≤4/2 | >64 | ≤16/4 | ≤2 | 128 | ≤0.12/4 | 128 | ≤0.12/4 | 32 | 64 | ≤0.5 | St Nal Cip Tet Sul Tp |
Fec 147 | CTX-M-10 | 8/4 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 2 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Sp Nal Sul Tp |
Fec 284X | CTX-M-9 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | >64 | ≤0.5 | Nal |
Fec 395 | CTX-M-9 | ≤4/2 | >64 | ≤16/4 | 4 | 128 | ≤0.12/4 | 4 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Tet Sul |
Fec 5 | CTX-M-9 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | 32 | ≤0.5 | St Sp Tet Sul Tp |
Fec 87 | CTX-M-9 | ≤4/2 | >64 | ≤16/4 | 8 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | 64 | ≤0.5 | St Sp Nal Cip Tet Sul Tp |
Fec 311 | CTX-M-9 | 8/4 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Sp Tet Sul Tp |
Fec 386 | CTX-M-9 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | ≤0.5 | ≤0.12/4 | >32 | 4 | ≤0.5 | St Sp Nal Cip Tet Sul Tp |
Fec 325 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | ≤2 | 128 | ≤0.12/4 | ≤0.5 | ≤0.12/4 | 32 | 2 | ≤0.5 | St Nal Tet Sul Tp |
Fec 327 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | 4 | 128 | ≤0.12/4 | 1 | ≤0.12/4 | 16 | 4 | ≤0.5 | St Nal Cip Tet Sul Tp Clo |
Fec 397 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | 32 | ≤0.5 | Nal |
Fec 166 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | ≤0.5 | ≤0.12/4 | 8 | 4 | ≤0.5 | Nal Tet Sul |
Fec 216 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | ≤0.5 | ≤0.12/4 | >32 | 4 | ≤0.5 | St Sp Nm Km Nal Cip Tet Sul Tp |
Fec 245 | CTX-M-14 | 8/4 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 2 | 0.25/4 | >32 | 8 | ≤0.5 | St Tet |
Fec 268 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 2 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Tet |
Fec 336 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 1 | ≤0.12/4 | >32 | >64 | ≤0.5 | Nal Cip Tet Sul Tp Clo |
Fec 383 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | 2 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Nm Sul Tp |
Fec 38 | Unknown | >16/8 | >64 | >64/4 | 8 | 128 | 4/4 | 1 | 0.25/4 | >32 | ≤0.5 | ≤0.5 | St Sp Tet Sul Tp Clo |
2003, healthy volunteers | |||||||||||||
VS 27 | CTX-M-2 like | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | 8 | ≤0.12/4 | >32 | >64 | ≤0.5 | Nal Cip Tet Sul |
VS 41 | SHV-12 | ≤4/2 | >64 | ≤16/4 | ≤2 | >128 | ≤0.12/4 | >128 | ≤0.12/4 | >32 | >64 | ≤0.5 | |
VS 85 | SHV-12 | ≤4/2 | >64 | ≤16/4 | ≤2 | 128 | ≤0.12/4 | 128 | ≤0.12/4 | 32 | 32 | ≤0.5 | Tet Sul |
VS 62 | CTX-M-14 | ≤4/2 | >64 | ≤16/4 | 4 | >128 | ≤0.12/4 | 2 | ≤0.12/4 | >32 | >64 | ≤0.5 | St Tet Sul Tp |
AMC, amoxicillin-clavulanate; PIP, piperacillin; P/T, piperacillin-tazobactam; CTX, cefotaxime; CTX-C, cefotaxime-clavulanate; CAZ, ceftazidime; CAZ-C, ceftazidime-clavulanate; CPM, cefepime; ATM, aztreonam; IMP, imipenem.